FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

0 vistas· 09/07/23
OncLive® On Air
OncLive® On Air
0 Suscriptores
0
En

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Mostrar más

 0 Comentarios sort   Ordenar por


Hasta la próxima